FindTrial
Sign In

Effects of menatetrenone on the osteoblastogenic potential of circulating mesenchymal stem cells in alendronate-treated patients with glucocorticoid-induced osteoporosis

Effects of menatetrenone on the osteoblastogenic potential of circulating mesenchymal stem cells in alendronate-treated patients with glucocorticoid-induced osteoporosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900020988
Enrollment
Unknown
Registered
2019-01-24
Start date
2015-01-01
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucocorticoid-induced osteoprosis

Interventions

Case series:menatetrenone, 15mg once, three times per day
Normal control group:None intervention

Sponsors

Tianjin Medical University General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 50-80 years old; 2. Alendronate-treated glucocorticoid-induced osteoporosis patients.

Exclusion criteria

Exclusion criteria: 1. The dosage of the prednisolone was changed during the observation; 2. Patients with diabetes, bone metabolic diseases, severe heart, lung, liver and kidney diseases, hematological diseases or tumor.

Design outcomes

Primary

MeasureTime frame
circulating osteoprogenitor cells;osteocalcin;N-terminal propeptide of type I collagen;ß-C-terminal telopeptide of type I collagen;alkaline phosphatase;—

Secondary

MeasureTime frame
serum calcium;serum phosphate;urinary calcium;parathyroid hormone;—

Countries

China

Contacts

Public ContactMei Zhu

Tianjin Medical University General Hospital

meichuqin@163.com+86 15802238239

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026